Journal article
High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
Journal of clinical medicine, Vol.11(6), p.1605
03/14/2022
DOI: 10.3390/jcm11061605
PMCID: PMC8953761
PMID: 35329928
Abstract
Background: Tumor mutation burden (TMB) is arising as a useful marker of checkpoint inhibitors' effectiveness in cancer patients in general and has been proposed as predictive in breast cancers. Despite the initial success of checkpoint inhibitors in triple-negative breast cancer, ER-positive breast cancers are less amenable to immunotherapy treatments due to the lower immunogenicity of this subset, associated with lower TMB and less pronounced inflammatory cell infiltration. However, a minority of ER-positive breast cancers do have a higher TMB and could be targets of immune checkpoint inhibitors. Methods: This investigation uses publicly available genomic data to examine ER-positive/HER2-negative or luminal breast cancers with high mutation numbers and compare them with cancers of the same subtype and low mutation numbers. Clinical characteristics and molecular correlates according to mutation numbers are described. Results: ER-positive/HER2-negative and luminal breast cancers with high mutation numbers have a higher prevalence of PIK3CA mutations and in some of the series examined mutations in TP53 and CDH1. A significant proportion of cancers with high mutation numbers carry mutations in microsatellite instability genes and genes involved in DNA damage response. Despite these differences, the prognosis of ER-positive/HER2-negative and luminal breast cancers with high mutation numbers is not significantly different compared to counterparts with lower mutation counts. Conclusions: These data may inform the potential suitability of these cancers for immunotherapy and could guide the development of rational combination therapies based on immune checkpoint inhibitors with other targeted drugs.
Details
- Title: Subtitle
- High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
- Creators
- Ioannis A. Voutsadakis - Essar Steel Algoma (Canada)
- Resource Type
- Journal article
- Publication Details
- Journal of clinical medicine, Vol.11(6), p.1605
- DOI
- 10.3390/jcm11061605
- PMID
- 35329928
- PMCID
- PMC8953761
- NLM abbreviation
- J Clin Med
- ISSN
- 2077-0383
- eISSN
- 2077-0383
- Publisher
- Mdpi
- Number of pages
- 18
- Language
- English
- Date published
- 03/14/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984806601202771
Metrics
3 Record Views